![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 6
2023
Behr, Jürgen 
ORCID: https://orcid.org/0000-0002-9151-4829; Nathan, Steven D. ORCID: https://orcid.org/0000-0002-6270-1617; Costabel, Ulrich ORCID: https://orcid.org/0000-0003-2804-9511; Albera, Carlo ORCID: https://orcid.org/0000-0002-0334-869X; Wuyts, Wim A.; Glassberg, Marilyn K. ORCID: https://orcid.org/0000-0003-1990-6614; Haller, Harold; Alvaro, Giuseppe; Gilberg, Frank; Samara, Katerina und Lancaster, Lisa
(2023):
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
In: Advances in Therapy, Bd. 40, Nr. 9: S. 3937-3955
[PDF, 840kB]
ORCID: https://orcid.org/0000-0002-9151-4829; Nathan, Steven D. ORCID: https://orcid.org/0000-0002-6270-1617; Costabel, Ulrich ORCID: https://orcid.org/0000-0003-2804-9511; Albera, Carlo ORCID: https://orcid.org/0000-0002-0334-869X; Wuyts, Wim A.; Glassberg, Marilyn K. ORCID: https://orcid.org/0000-0003-1990-6614; Haller, Harold; Alvaro, Giuseppe; Gilberg, Frank; Samara, Katerina und Lancaster, Lisa
(2023):
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
In: Advances in Therapy, Bd. 40, Nr. 9: S. 3937-3955
[PDF, 840kB]
2022
Harari, Sergio; Wells, Athol U.; Wuyts, Wim A.; Nathan, Steven D.; Kirchgaessler, Klaus-Uwe; Bengus, Monica und Behr, Juergen
(2022):
The 6-min walk test as a primary end-point in interstitial lung disease.
In: European Respiratory Review, Bd. 31, Nr. 165, 220087
2021
Behr, Jürgen; Nathan, Steven D.; Wuyts, Wim A.; Bishop, Nesrin Mogulkoc; Bouros, Demosthenes E.; Antoniou, Katerina; Guiot, Julien; Kramer, Mordechai R.; Kirchgaessler, Klaus-Uwe; Bengus, Monica; Gilberg, Frank; Perjesi, Andras; Harari, Sergio und Wells, Athol U.
(2021):
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
In: Lancet Respiratory Medicine, Bd. 9, Nr. 1: S. 85-95
Nathan, Steven D.; Cottin, Vincent; Behr, Jürgen; Hoeper, Marius M.; Martinez, Fernando J.; Corte, Tamera J.; Keogh, Anne M.; Leuchte, Hanno; Mogulkoc, Nesrin; Ulrich, Silvia; Wuyts, Wim A.; Yao, Zhen; Ley-Zaporozhan, Julia; Mueller-Lisse, Ullrich G.; Scholle, Frank-Detlef; Brueggenwerth, Guenther; Busse, Dennis; Nikkho, Sylvia und Wells, Athol U.
(2021):
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study.
In: Journal of Heart and Lung Transplantation, Bd. 40, Nr. 6: S. 494-503
2019
Nathan, Steven D.; Behr, Jürgen; Collard, Harold R.; Cottin, Vincent; Hoeper, Marius M.; Martinez, Fernando J.; Corte, Tamera J.; Keogh, Anne M.; Leuchte, Hanno; Mogulkoc, Nesrin; Ulrich, Silvia; Wuyts, Wim A.; Yao, Zhen; Boateng, Francis und Wells, Athol U.
(2019):
Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
In: Lancet Respiratory Medicine, Bd. 7, Nr. 9: S. 780-790
Nathan, Steven D.; Costabel, Ulrich; Albera, Carlo; Behr, Jürgen; Wuyts, Wim A.; Kirchgaessler, Klaus-Uwe; Stauffer, John L.; Morgenthien, Elizabeth; Chou, Willis; Limb, Susan L. und Noble, Paul W.
(2019):
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
In: Respiratory Medicine, Bd. 153: S. 44-51